Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience

about

Use of direct antiviral agents in liver transplant recipients with hepatitis C virus in Korea: 2-center experience

Item

http://www.wikidata.org/entity/Q57213140

description

scientific article published on 31 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Use of direct antiviral agents ...... in Korea: 2-center experience

@en

Use of direct antiviral agents ...... in Korea: 2-center experience

@nl

type

Item

label

Use of direct antiviral agents ...... in Korea: 2-center experience

@en

Use of direct antiviral agents ...... in Korea: 2-center experience

@nl

prefLabel

Use of direct antiviral agents ...... in Korea: 2-center experience

@en

Use of direct antiviral agents ...... in Korea: 2-center experience

@nl

P1476

Use of direct antiviral agents ...... in Korea: 2-center experience

@en

P2093

Choon Hyuck David Kwon

http://www.w3.org/2001/XMLSchema#string

Dong-Hyun Sinn

http://www.w3.org/2001/XMLSchema#string

Gyu-Seong Choi

http://www.w3.org/2001/XMLSchema#string

Jae-Won Joh

http://www.w3.org/2001/XMLSchema#string

Jong Man Kim

http://www.w3.org/2001/XMLSchema#string

Kyung-Suk Suh

http://www.w3.org/2001/XMLSchema#string

Nam-Joon Yi

http://www.w3.org/2001/XMLSchema#string

P2860

KASL clinical practice guidelines: management of hepatitis C

Outcomes for patients with HCV after liver transplantation in Korea: a multicenter study

PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus.

Perspectives on treating hepatitis C infection in the liver transplantation setting.

Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.

Sofosbuvir/Ledipasvir Without Ribavirin Achieved High Sustained Virologic Response for Hepatitis C Recurrence After Liver Transplantation: Two-Center Experience.

Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients.

Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.

Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience.

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

P304

147-151

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4174/ASTR.2018.95.3.147

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kwang-Woong Lee

P577

2018-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30182021

http://www.w3.org/2001/XMLSchema#string

P932

6121168

http://www.w3.org/2001/XMLSchema#string